AI Verdict
IMRX has stronger fundamentals based on our AI analysis.
IMRX vs IMNN Fundamental Comparison
| Metric | IMRX | IMNN |
|---|---|---|
| Revenue | $0.0 | $500,000.0 |
| Net Income | $-56.0M | $-14.5M |
| Net Margin | N/A | -2,899.0% |
| ROE | -25.6% | -205.3% |
| ROA | -24.2% | -118.0% |
| Current Ratio | 17.50x | 2.32x |
| Debt/Equity | 0.00x | 0.86x |
| EPS | $-1.27 | $-6.83 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
IMRX vs IMNN: Frequently Asked Questions
Is IMRX or IMNN a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), IMRX has stronger fundamentals. IMRX is rated SELL (72% confidence) while IMNN is rated STRONG SELL (95% confidence). This is not investment advice.
How does IMRX compare to IMNN fundamentally?
Immuneering Corp has ROE of -25.6% vs Imunon, Inc.'s -205.3%. Net margins are N/A vs -2,899.0% respectively.
Which stock pays higher dividends, IMRX or IMNN?
IMRX has a dividend yield of N/A or no dividend while IMNN has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in IMRX or IMNN for long term?
For long-term investing, consider that IMRX has SELL rating with 72% confidence, while IMNN has STRONG SELL rating with 95% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about IMRX vs IMNN?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For IMRX vs IMNN, the AI consensus favors IMRX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.